The Role for NKAP in iNKT cell development
The Role for NKAP in iNKT cell development
批准号:
8087797
负责人:
Virginia Smith Shapiro
金额:
$23.66万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-08-15 至 2013-07-31
关键词:
AlphaproteobacteriaAntigensAutoimmune DiseasesAutoimmunityBacteriaBorreliaCD8B1 geneCell physiologyCellsClinical TrialsDefectDevelopmentDiabetes MellitusFailureFamilyGene ExpressionGenerationsGeneticGenetic RecombinationGlycolipidsHourImmune responseLyme DiseaseLymphocyteMalignant NeoplasmsModelingMolecularMusNamesPathway interactionsPhaseRoleSLAM proteinStagingT-Cell DevelopmentT-Cell ReceptorT-LymphocyteThymocyte DevelopmentTranscription Repressor/CorepressorTransgenesbasechemokinecytokinefightinggraft vs host diseasenotch proteinnovelpathogenreceptorthymocytetumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): NKT cells are a unique innate lineage of lymphocytes which express a¿ T cell receptors of limited diversity and recognize glycolipid antigens presented on MHC-like CD1d molecules. A subset of NKT cells express an invariant TCR1 chain, Va14-Ja18 in mice, and are thus named iNKT ("invariant NKT cells"). NKT cells respond quickly to antigenic stimulation, producing significant quantities of cytokines and chemokines within minutes or hours, which regulate the immune response. In addition to having an important role in the clearance of a subset of alpha-proteobacteria, iNKT cells have also been shown to regulate tumor surveillance and tumor rejection, autoimmune diseases, and graft versus host disease (GVHD). Because of their anti-tumor effects, clinical trials are underway to mobilize and activate iNKT cells in fighting cancer. iNKT cells develop via a distinct pathway from 'conventional' a¿ T cells, although they share CD4+CD8+ (DP) thymocytes as a common precursor. We have recently cloned a novel transcriptional repressor, NKAP, from a genetic complementation screen. Previously, we demonstrated that NKAP is required early in T cell development, as conditional deletion of NKAP, using an Lck-cre transgene, results in an early block in a¿ T cell development but leaves ?d T cell development unaffected. To understand the function of NKAP later in a¿ T cell development, we generated CD4-cre NKAP cKO mice, which delete NKAP efficiently at the DP stage of thymocyte development. Loss of NKAP expression in DP T cells leads to a complete abrogation of iNKT cell development, while conventional a¿ T cell development is unaffected. This defect in iNKT cell generation is not due to lack of CD1d expression in DP T cells, nor in their expression of two Slam family receptors that are critical to iNKT cell development, Slamf1 (also known as CD150) and Slamf6 (also known as Ly108). In this proposal, we will define the molecular cause(s) for the failure in the development of iNKT cells in the absence of NKAP.
PUBLIC HEALTH RELEVANCE: Invariant NKT cells (iNKT) are critical to generating an immune response against pathogens, including Borrelia (the genus of bacteria responsible for Lyme disease). In addition, activation of iNKT cells can ameliorate autoimmunity in the NOD model of diabetes. Phase I/II clinical trials in which iNKT cells are activated to harness anti-tumor activity have been initiated. This proposal will focus on understanding the role of NKAP in the generation and activation of iNKT cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Altered TCR signaling in anergy
-
批准号:10750486
-
项目类别:
-
资助金额:$24.21万
-
财政年份:2023
-
负责人:Virginia Smith Shapiro
-
依托单位:
Training Program in Immunology
-
批准号:10493678
-
项目类别:
-
资助金额:$15.84万
-
财政年份:2022
-
负责人:Virginia Smith Shapiro
-
依托单位:
Training Program in Immunology
-
批准号:10650170
-
项目类别:
-
资助金额:$32.29万
-
财政年份:2022
-
负责人:Virginia Smith Shapiro
-
依托单位:
Regulation of B cell development by ABCB7
-
批准号:10374116
-
项目类别:
-
资助金额:$19.88万
-
财政年份:2021
-
负责人:Virginia Smith Shapiro
-
依托单位:
Regulation of gene expression by HDAC3
-
批准号:10455700
-
项目类别:
-
资助金额:$50.57万
-
财政年份:2020
-
负责人:Virginia Smith Shapiro
-
依托单位:
Regulation of gene expression by HDAC3
-
批准号:10225415
-
项目类别:
-
资助金额:$50.57万
-
财政年份:2020
-
负责人:Virginia Smith Shapiro
-
依托单位:
Regulation of gene expression by HDAC3
-
批准号:10667604
-
项目类别:
-
资助金额:$50.57万
-
财政年份:2020
-
负责人:Virginia Smith Shapiro
-
依托单位:
ST8Sia6 expression on tumors inhibits the immune response
-
批准号:10308083
-
项目类别:
-
资助金额:$39.14万
-
财政年份:2019
-
负责人:Virginia Smith Shapiro
-
依托单位:
ST8Sia6 expression on tumors inhibits the immune response
-
批准号:10529298
-
项目类别:
-
资助金额:$39.14万
-
财政年份:2019
-
负责人:Virginia Smith Shapiro
-
依托单位:
ST8Sia6 expression on tumors inhibits the immune response
-
批准号:9913027
-
项目类别:
-
资助金额:$40.6万
-
财政年份:2019
-
负责人:Virginia Smith Shapiro
-
依托单位:
ST8Sia6 expression on tumors inhibits the immune response
-
批准号:10054986
-
项目类别:
-
资助金额:$39.94万
-
财政年份:2019
-
负责人:Virginia Smith Shapiro
-
依托单位:
Regulation of T cell development by HDAC3
-
批准号:9543129
-
项目类别:
-
资助金额:$60.29万
-
财政年份:2017
-
负责人:Virginia Smith Shapiro
-
依托单位:
Regulation of hematopoietic stem cell maintenance and survival by NKAP
-
批准号:8823656
-
项目类别:
-
资助金额:$39.15万
-
财政年份:2013
-
负责人:Virginia Smith Shapiro
-
依托单位:
Regulation of hematopoietic stem cell maintenance and survival by NKAP
-
批准号:8531478
-
项目类别:
-
资助金额:$37.84万
-
财政年份:2013
-
负责人:Virginia Smith Shapiro
-
依托单位:
Regulation of hematopoietic stem cell maintenance and survival by NKAP
-
批准号:8666663
-
项目类别:
-
资助金额:$38.96万
-
财政年份:2013
-
负责人:Virginia Smith Shapiro
-
依托单位:
Regulation of hematopoietic stem cell maintenance and survival by NKAP
-
批准号:9040250
-
项目类别:
-
资助金额:$39.75万
-
财政年份:2013
-
负责人:Virginia Smith Shapiro
-
依托单位:
The Role for NKAP in iNKT cell development
-
批准号:8316095
-
项目类别:
-
资助金额:$19.71万
-
财政年份:2011
-
负责人:Virginia Smith Shapiro
-
依托单位:
Regulation of T cell development and maturation by NKAP
-
批准号:8011439
-
项目类别:
-
资助金额:$37.4万
-
财政年份:2010
-
负责人:Virginia Smith Shapiro
-
依托单位:
Regulation of T cell maturation
-
批准号:9190269
-
项目类别:
-
资助金额:$39.75万
-
财政年份:2010
-
负责人:Virginia Smith Shapiro
-
依托单位:
Regulation of T cell development and maturation by NKAP
-
批准号:8415926
-
项目类别:
-
资助金额:$35.15万
-
财政年份:2010
-
负责人:Virginia Smith Shapiro
-
依托单位:
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
-
批准号:2022J011295
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:王亚伟
-
依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
-
批准号:30801055
-
项目类别:青年科学基金项目
-
资助金额:19.0万元
-
批准年份:2008
-
负责人:王丽梅
-
依托单位: